Insider Buying: ProQR Therapeutics (NASDAQ:PRQR) CEO Buys $261,000.00 in Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) CEO Boer Daniel Anton De purchased 150,000 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were purchased at an average price of $1.74 per share, with a total value of $261,000.00. Following the acquisition, the chief executive officer directly owned 300,000 shares in the company, valued at $522,000. This represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Boer Daniel Anton De also recently made the following trade(s):

• On Tuesday, July 7th, Boer Daniel Anton De purchased 150,000 shares of ProQR Therapeutics stock. The stock was acquired at an average price of $1.59 per share, for a total transaction of $238,500.00.

ProQR Therapeutics Price Performance

ProQR Therapeutics stock opened at $1.73 on Monday. ProQR Therapeutics N.V. has a 52-week low of $1.33 and a 52-week high of $3.10. The firm’s fifty day moving average is $1.62 and its 200 day moving average is $1.68. The company has a market cap of $182.28 million, a price-to-earnings ratio of -3.46 and a beta of 0.04.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. The firm had revenue of $2.35 million during the quarter, compared to the consensus estimate of $5.19 million. On average, equities research analysts anticipate that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PRQR has been the topic of a number of recent analyst reports. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Weiss Ratings cut shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Wall Street Zen lowered ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. JonesTrading decreased their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Finally, Chardan Capital lowered their target price on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, June 26th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Hedge Funds Weigh In On ProQR Therapeutics

A number of large investors have recently made changes to their positions in the business. Osaic Holdings Inc. boosted its position in shares of ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares in the last quarter. Persistent Asset Partners Ltd increased its position in ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after buying an additional 8,874 shares in the last quarter. Diadema Partners LP raised its stake in ProQR Therapeutics by 6.2% in the fourth quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 9,838 shares during the last quarter. Bank of America Corp DE raised its stake in ProQR Therapeutics by 6.4% in the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 11,186 shares during the last quarter. Finally, Raymond James Financial Inc. boosted its holdings in ProQR Therapeutics by 15.2% in the third quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 14,549 shares in the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.